Tag Archives: Becton Dickinson

Anticipated Earnings for Becton Dickinson (BDX) To Fall

By Narrative Science Analysts are looking for decreased profit for Becton Dickinson when the company reports its results for the third quarter on Thursday, August 1, 2013. Becton Dickinson reported profit of $1.52 a year ago, but the consensus estimate calls for earnings per share of $1.47 this time around. …read more

Source: FULL ARTICLE at Forbes Markets

Becton Dickinson Buys Cato Software

By Rich Smith, The Motley Fool

Filed under:

Franklin Lakes, N.J.-based Becton, Dickinson and Company  has bought medication “safety solutions” software maker Cato Software Solutions for an undisclosed sum, as BD confirmed Tuesday.

Vienna, Austria-based Cato produces software that automates the creation and sharing of data aimed at reducing human error, standardizing practices, and streamlining workflow in the process of delivering drugs in both pharmacy and clinical settings. In essence, the software tells drug dispensers how and how much of a drug to distribute, with the aim of reducing medical errors. As such, the business would tend to enhance BD‘s prefillable drug delivery systems and related businesses. In a statement, BD Medical-Medical Surgical Systems President William A. Tozzi predicted the Cato acquisition would “help us accelerate BD‘s growth, especially in the pharmacy segment.”

Specific financial terms of the acquisition were not disclosed, although BD did allow that the transaction will probably be “minimally dilutive” in fiscal 2013. In any case, the company confirmed that the Cato purchase will not affect the firm’s earnings guidance for this year.

In BD‘s Feb. Q1 2013 earnings release, the company guided investors to expect 3.5% to 4% revenue growth this year, with diluted earnings per share from continuing operations probably coming in between $5.69 and $5.72, resulting in 6% to 6.5% earnings growth year over year.

The article Becton Dickinson Buys Cato Software originally appeared on Fool.com.

Fool contributor Rich Smith has no position in any stocks mentioned. The Motley Fool recommends Becton Dickinson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
if (obj.addEventListener){
obj.addEventListener(evType, fn, useCapture);
return true;
} else if (obj.attachEvent){
var r = obj.attachEvent("on"+evType, fn);
return r;
}
}

addEvent(window, "load", function(){new FoolVisualSciences();})
addEvent(window, "load", function(){new PickAd();})

var themeName = 'dailyfinance.com';
var _gaq = _gaq || [];
_gaq.push(['_setAccount', 'UA-24928199-1']);
_gaq.push(['_trackPageview']);

(function () {

var ga = document.createElement('script');
ga.type …read more
Source: FULL ARTICLE at DailyFinance

Why Becton Dickinson Is Poised to Outperform

By Brian Pacampara, Pacampara, The Motley Fool

Filed under:

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool’s free investing community, medical-device maker Becton, Dickinson and Company has earned a coveted five-star ranking.

With that in mind, let’s take a closer look at Becton Dickinson and see what CAPS investors are saying about the stock right now.

Becton Dickinson facts

Headquarters (founded)

Franklin Lakes, N.J. (1897)

Market Cap

$17.4 billion

Industry

Health care equipment

Trailing-12-Month Revenue

$7.8 billion

Management

Chairman/CEO Vincent Forlenza
Acting CFO Suketu Upadhyay

Return on Equity (average, past 3 years)

23.9%

Cash/Debt

$2.5 billion / $4.2 billion

Dividend Yield

2.2%

Competitors

Abbott Labs
Baxter International
Covidien

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 98% of the 1,168 members who have rated Becton Dickinson believe the stock will outperform the S&P 500 going forward.

Earlier this month, one of those Fools, bloomr, succinctly summed up the Becton Dickinson bull case for our community: “The population is getting older. … Diabetes is an epidemic. Everybody hates needles, but [Becton Dickinson] has been a leader for years with a consistently solid dividend yield to boot.”

If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong five-star rating, Becton Dickinson may not be your top choice.

If that’s the case, we’ve compiled a special free report for investors called “The 3 Dow Stocks Dividend Investors Need,” which uncovers a few other juicy income opportunities. The report is 100% free, but it won’t be around forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

The article Why Becton Dickinson Is Poised to Outperform originally appeared on Fool.com.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Becton Dickinson and Covidien. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
…read more
Source: FULL ARTICLE at DailyFinance